INTRODUCTION
============

In light of recent articles that have reported no significant differences in oncological results between hemithyroidectomy and total thyroidectomy in patients with low- to intermediate-risk papillary thyroid carcinoma, the indications for hemithyroidectomy have been expanded \[[@b1-ceo-2019-01634],[@b2-ceo-2019-01634]\]. However, controversy regarding central neck dissection persists, even in cases of hemithyroidectomy, given that occult nodal metastasis in the central compartment has been observed in approximately one-half of patients clinically diagnosed with N0 papillary carcinoma \[[@b3-ceo-2019-01634],[@b4-ceo-2019-01634]\]. Some meta-analyses have investigated the effectiveness of prophylactic central neck dissection performed with total thyroidectomy \[[@b5-ceo-2019-01634]-[@b7-ceo-2019-01634]\], but not in patients undergoing hemithyroidectomy alone. The purpose of this study, therefore, was to evaluate the oncological effect of prophylactic central neck dissection performed during hemithyroidectomy in patients with low- to intermediate-risk papillary thyroid carcinoma.

MATERIALS AND METHODS
=====================

Literature search
-----------------

The Embase and Medline database was searched on June 3, 2019 using the terms "papillary thyroid carcinoma," "hemithyroidectomy," "lobectomy," and "central OR node."

Inclusion criteria
------------------

Observational studies published as full-text articles in English were screened using following inclusion criteria: performance of central neck dissection was clearly stated; extent of thyroidectomy was clearly defined, and data regarding hemithyroidectomy were separately reported; recurrence was reported separately according to site (i.e., contralateral thyroid, and central and lateral compartments); and studies included patients with low to intermediate risk papillary thyroid carcinoma.

Data analysis
-------------

There were only two comparative studies; as such, all observational studies reporting oncological results after hemithyroidectomy---with or without central neck dissection---were searched and underwent proportional meta-analysis. The recurrence rate was calculated for the contralateral thyroid, and central and lateral compartments, separately. The proportional meta-analysis was performed using StatsDirect Ver. 3 (Cheshire, UK) and comprehensive meta-analysis (Biostat, Englewood, NJ, USA). Forest plots were constructed using Excel (Microsoft Corp., Redmond, WA, USA). Quality assessment of the included articles was performed using the risk of bias assessment tool for non-randomized studies (RoBNAS) and Review Manager ver. 5.3 (Cochrane Collaboration, Copenhagen, Denmark).

RESULTS
=======

In total, 687 records were retrieved from the Embase database after removal of duplicates. Upon screening article titles, 621 irrelevant records were excluded. The abstract and full text of 66 records were screened, and 14 were included in the quantitative analysis. The articles published by Ebina et al. \[[@b8-ceo-2019-01634]\] and Liu et al. \[[@b9-ceo-2019-01634]\] reported follow-up data for patients who underwent hemithyroidectomy with central neck dissection, but were excluded. In the study by Ebina et al. \[[@b8-ceo-2019-01634]\], the extent of hemithyroidectomy was unclear and many subtotal thyroidectomies were included. In the study by Liu et al. \[[@b9-ceo-2019-01634]\], 62.8% of patients exhibited lateral neck metastasis, and it appeared that the researchers applied different indications from what is generally accepted ([Fig. 1](#f1-ceo-2019-01634){ref-type="fig"}).

[Table 1](#t1-ceo-2019-01634){ref-type="table"} summarizes the outcomes of the 14 studies that were ultimately included in the analysis \[[@b10-ceo-2019-01634]-[@b23-ceo-2019-01634]\]. Two studies investigated the impact of prophylactic central neck dissection in hemithyroidectomy using a comparative method \[[@b11-ceo-2019-01634],[@b19-ceo-2019-01634]\]. Six investigations compared oncological results between total thyroidectomy and hemithyroidectomy in various subjects; however, only the data regarding hemithyroidectomy were included in the present study \[[@b10-ceo-2019-01634],[@b12-ceo-2019-01634],[@b13-ceo-2019-01634],[@b20-ceo-2019-01634],[@b21-ceo-2019-01634],[@b23-ceo-2019-01634]\]. Others compared recurrence according to various factors among patients who underwent hemithyroidectomy \[[@b14-ceo-2019-01634]-[@b18-ceo-2019-01634],[@b22-ceo-2019-01634]\]. The patients included were mostly those with a tumor size \<4 cm and no clinical preoperative lymph node metastasis. The rates of developing new carcinoma in the contralateral thyroid, lymph node metastasis in the central compartment, and lymph node metastasis in the lateral compartment were calculated separately. In studies in which routine central neck dissection was performed, the rate of occult metastasis in the central compartment was found to range from 28.0% to 59.65%.

In the quality assessment according to the RoBNAS criteria, most studies were found to be free of problems. Kwon et al. \[[@b13-ceo-2019-01634]\] did not report oncological results from all patients; results were only reported for 688 of the 755 patients used for case-control matching. Vaisman et al. \[[@b21-ceo-2019-01634],[@b22-ceo-2019-01634]\] included cases other than papillary carcinoma in both studies. Xue et al. \[[@b23-ceo-2019-01634]\] only selected cases of multifocal papillary thyroid carcinoma. Therefore, these four studies were classified as having a high risk of bias in participant selection. Vaisman et al. \[[@b22-ceo-2019-01634]\] did not clearly describe the number of patients who underwent central neck dissection, although the authors reported that they did not routinely perform prophylactic central neck dissection; therefore, their study was classified as having a high risk of bias in confounding variables. Studies by Kuba et al. \[[@b12-ceo-2019-01634]\] and Matsuzu et al. \[[@b16-ceo-2019-01634]\] did not report lymph node metastasis in the central and lateral compartments separately. Park et al. \[[@b18-ceo-2019-01634]\] did not report recurrence in the contralateral thyroid and, in one study by Vaisman et al. \[[@b22-ceo-2019-01634]\], the follow-up period was too short (12 months; range, 3--28 months), making it difficult to calculate the true recurrence rate. Thus, these studies were classified as having a high risk for bias in incomplete outcome data ([Fig. 2](#f2-ceo-2019-01634){ref-type="fig"}).

In the proportional meta-analysis, central compartment recurrence occurred in 0% to 1.75% of cases, with a mean of 0.17% when prophylactic central neck dissection was performed. When it was not performed, the recurrence rate was found to be 0% to 6.4%, with a mean of 1.78%. A between-group comparison according to whether prophylactic central neck dissection was performed yielded a significant difference (*P*=0.018) ([Fig. 3A](#f3-ceo-2019-01634){ref-type="fig"}). Lateral compartment recurrence demonstrated no difference according to whether prophylactic central neck dissection was performed; the recurrence rate ranged from 0% to 3.72%, with a mean of 1.31% ([Fig. 3B](#f3-ceo-2019-01634){ref-type="fig"}). Carcinoma in the contralateral thyroid was observed in 2.17% to 24.6% of cases, with a mean of 5.44% in total; no significant difference was found according to whether central neck dissection was performed ([Fig. 3C](#f3-ceo-2019-01634){ref-type="fig"}).

DISCUSSION
==========

Although many studies have investigated the issue, controversy continues regarding the value of prophylactic central neck dissection. In the American Thyroid Association (ATA) guidelines published in 2016, prophylactic central neck dissection was not recommended for T1- or T2-differentiated thyroid cancers \[[@b24-ceo-2019-01634]\]. The authors of the guideline stated that prophylactic central neck dissection can identify a substantial number of pN1 patients; however, the direct effect of this procedure is small. Another problem with central neck dissection during total thyroidectomy is that morbidity can be excessively high when an inexperienced surgeon is operating.

Some meta-analyses have analyzed the effect of central neck dissection in patients undergoing total thyroidectomy. A common finding of those studies is that prophylactic central neck dissection reduced locoregional recurrence from 4.59%--8.6% to 2.52%--5.9% \[[@b5-ceo-2019-01634]-[@b7-ceo-2019-01634],[@b25-ceo-2019-01634]\]. This change in locoregional recurrence was due to decreased recurrence in the central compartment, but not in the lateral compartment \[[@b7-ceo-2019-01634]\]. However, radioactive iodine therapy and thyroid-stimulating hormone (TSH) suppression can be a confounding factor for this reduction in regional recurrence rates. When a tumor is pathologically diagnosed as N1 by central neck dissection, radioactive iodine therapy may be used with a higher dose and more stringent TSH suppression will be applied. Therefore, although there is no clear evidence that the addition of radioactive iodine therapy or TSH suppression reduces recurrence, postoperative treatment could be a confounding variable. In contrast, morbidity is significantly increased by central neck dissection in patients undergoing total thyroidectomy. According to previous meta-analyses, the risk for recurrent laryngeal nerve paralysis did not change according to whether central neck dissection was performed. However, central neck dissection significantly increased the risk of transient and permanent hypocalcemia \[[@b5-ceo-2019-01634]-[@b7-ceo-2019-01634]\]. Therefore, balancing the risks and benefits of central neck dissection is an important consideration in patients undergoing total thyroidectomy.

Until the revised ATA guideline was published in 2016, total thyroidectomy was regarded as the optimal surgical procedure in most cases of papillary thyroid carcinoma. However, recent reports describing outcomes in patients receiving active surveillance for papillary microcarcinoma have significantly changed surgeons' approach to thyroid surgery \[[@b26-ceo-2019-01634],[@b27-ceo-2019-01634]\], and hemithyroidectomy---as a more conservative procedure---is now regarded as optimal in many instances, even in the revised ATA guidelines \[[@b24-ceo-2019-01634]\]. Nevertheless no meta-analyses have yet investigated the effects of central neck dissection in hemithyroidectomy. In addition, radioactive iodine therapy is not possible after hemithyroidectomy, and TSH suppression is not applied or only minimally applied. Therefore, we believed that it would be possible to substantiate the benefit of prophylactic central neck dissection in hemithyroidectomy, while excluding other confounding factors.

Because hypocalcemia rarely occurs after hemithyroidectomy, this meta-analysis only analyzed clinical outcomes involving recurrence. In total, recurrence in the contralateral thyroid lobe was observed in 5.4% of patients, without a significant difference according to whether central neck dissection was performed, as expected. Recurrence in the lateral compartment was also not affected by central neck dissection, with an average recurrence rate of 1.31%. However, the recurrence rate in the central compartment was significantly lower in patients who underwent prophylactic central neck dissection (0.17% vs. 1.78%). This result is consistent with a previous meta-analysis investigating total thyroidectomy, and it clearly demonstrates the benefit of prophylactic central neck dissection without confounding factors. Although the benefit may be very small, we believe it is meaningful to minimize the recurrence rate, in that if recurrence is found later, patients can take medication for the rest of their lifetime after completion thyroidectomy with neck dissection. The side of recurrence in the central compartment has not been described in previous papers, with the exception of Hyun et al. \[[@b11-ceo-2019-01634]\], who described the side as unilateral. In conclusion, prophylactic central neck dissection during hemithyroidectomy for low- to intermediate-risk patients reduced the rate of recurrence in the central compartment by 1.6%.

HIGHLIGHTS
==========

▪ Recurrence in the central compartment was lower in the central neck dissection (CND) group.

▪ The central compartment recurrence rate was 0.17% with CND and 1.78% without CND.

▪ The lateral compartment recurrence rate was 1.3%, with no difference according to whether CND was performed.

▪ New carcinoma in the contralateral lobe was observed in 5.4% of cases overall.
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Summary of 14 included studies

  Study                                                Institute                                               Year                                                                                                                    No. of cases                                                        CND                                                                          Inclusion criteria                                                                                                           Demographic finding                                                                                                        Follow-up period        Outcome analysis                                                                             Recurrence
  ---------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Choi et al. (2019) \[[@b10-ceo-2019-01634]\]         Yonsei University, Korea                                1978--2011                                                                                                              974                                                                 Routine CND                                                                  1--4 cm, DTC (PTC, 97.5%; FTC, 2.5%)                                                                                         Tumor size: 1.6 cm, multiple: 15.6%, bilateral nodule: 5.3%, ETE: 46.3%, pN1a: 32.3%                                       57.3±58.1 mo            Comparison of oncologic result after TT vs. lobectomy in 1--4 cm size DTC                    Contralateral lobe: 87, operation bed: 1, central node: 0, lateral node: 1
  Hyun et al. (2012) \[[@b11-ceo-2019-01634]\]         Asan Medical Center, Korea                              2001--2009                                                                                                              105 (152 before exclusion of cases with completion thyroidectomy)   CND+: 42 (65 before excluding completion)                                    PTMC ≤1 cm, no clinically apparent ETE, cN0, M0 from ENT department                                                          \>1 cm: 5%, multiple: 14%, ETE: 37%, N1a: 29%                                                                              51.31±25.89 mo          Oncologic outcome according to CND in lobectomy cases                                        Contralateral lobe: 1,
  CDN--: 63 (87 before excluding completion)           \>1 cm: 10%, multiple: 10%, ETE: 43%, N1a: unknown      Contralateral lobe only: 5, contralateral lobe+ central: 2, contralateral lobe+central+lateral: 1, central+lateral: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Kuba et al. (2017) \[[@b12-ceo-2019-01634]\]         Nagasaki University, Japan                              1994--2008                                                                                                              120                                                                 Routine CND; 30 cases without preoperative diagnosis of PTC didn't do CND.   1--5 cm Thyroid cancer, cN0, cM0                                                                                             Tumor size: 1.7 (1.2--2.2), multiple: 21.7%, ETE: 39.2%, pN1a: 40.8%                                                       112 mo (11--250 mo)     Oncologic outcome between TT vs. lobectomy                                                   Thyroid and lymph node: 5, lymph node: 4 (central and lateral compartment is not specified)
  Kwon et al. (2017) \[[@b13-ceo-2019-01634]\]         Asan Medical Center, Korea                              1998--2007                                                                                                              688                                                                 Routine CND                                                                  PTMC only. N1b, M1 is excluded. Lobectomy and TT were one-to-one matched according to factors from internal medicine dept.   Before one-to-one matching (n=755), tumor size: 0.6 (0.5--0.8), ETE: 36%, multiple: 10%, N1a: 28%                          8.5 yr                  Oncologic outcome between TT vs. lobectomy in PTMC                                           Contralateral lobe: 22, central node: 0, lateral node: 4
  Lee et al. (2014) \[[@b14-ceo-2019-01634]\]          Yonsei University, Korea                                1986--2001                                                                                                              281                                                                 Routine CND                                                                  PTMC only; exclusion: multifocal PTC, definite ETE, cN+, RT history                                                          Tumor size: 0.68±0.27, 0.56±0.23, 9.3% and 8.8%; ETE: 51.2% and 23.9% for pN1a and pN0, respectively                       12.7 yr (4--24 yr)      Oncologic outcome between pN1a vs. pN0 in PTMC                                               Contralateral lobe: 18, contralateral lobe+lateral node: 1, lateral node: 2
  Li et al. (2013) \[[@b15-ceo-2019-01634]\]           Tianjin Medical University, China                       2006--2007                                                                                                              135                                                                 Routine CND                                                                  PTMC, no ETE, cN0, ipsilateral disease                                                                                       NC                                                                                                                         40.0±6.55 mo            Oncologic outcome between solitary vs. multiple PTC                                          Contralateral lobe: 6
  Matsuzu et al. (2013) \[[@b16-ceo-2019-01634]\]      Yokohama City University, Japan                         1986--1995                                                                                                              1,088                                                               Routine CND and LND; CND only: 60, CND+LND: 898, no ND: 130                  Consecutive cases of lobectomy for PTC with more than 5-year follow-up                                                       Tumor size: ≤1 cm: 14.3%, 1--2 cm: 33.7%, 2--4 cm: 41.9%, \>4 cm: 10%; ETE: 7.7%, multiple: 14.6%, cN+: 6.3%, pN+: 86.3%   17.6 yr                 Long-term follow-up data of lobectomy                                                        Contralateral lobe: 52, lymph node: 92, distant: 35 (central and lateral compartment is not specified)
  Park et al. (2017) \[[@b17-ceo-2019-01634]\]         Korea University, Korea                                 2004--2016                                                                                                              734                                                                 Not performed                                                                PTC confined to one thyroid, cN0, M0                                                                                         Tumor size: ≤1 cm: 90.6%, 1--2 cm: 8.6%, \>2 cm: 0.8%; ETE: 25.9%, multiple: 13.2%                                         50.4 mo (12--152 mo)    Oncologic result after lobectomy without CND                                                 Contralateral lobe: 17, contralateral lobe+latera node: 1, contralateral lobe+central+lateral node: 2, central node: 1, central+lateral node: 2
  Park et al. (2018) \[[@b18-ceo-2019-01634]\]         Asan Medical Center, Korea                              1998--2008                                                                                                              1,047                                                               Routine CND                                                                  Solitary intrathyroidal classic PTC ≤1 cm, from GS dept                                                                      Tumor size: 0.86±0.45; ETE: 43.1%, multiple: 8.6%, pN1a: 34.9%                                                             107 mo (12--216 mo)     Prognostic value of serum TSH level in lobectomy                                             Central node: 1, lateral node: 36, lateral node+distant meta: 3, distant meta: 2 (no description about contralateral lobe recurrence)
  Son et al. (2017) \[[@b19-ceo-2019-01634]\]          Catholic University of Daegu, Korea                     2005--2015                                                                                                              537                                                                 CND+: 399                                                                    PTC \<1 cm, pN0, M0, follow-up \>24 months                                                                                   Tumor size: 0.45 (0.1--1.0); ETE: 5.8%, multiple: 7.3%                                                                     56 mo (24--117 mo)      Oncologic outcome according to CND in lobectomy cases                                        Contralateral lobe: 9, central node: 4, lateral node: 9
  CND--: 138                                           Tumor size: 0.6 (0.1--1.0), ETE: 9.4%, multiple: 5.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Song et al. (2019) \[[@b20-ceo-2019-01634]\]         Asan Medical Center, Korea                              1998--2007                                                                                                              381                                                                 Routine CND                                                                  1 cm ≤Tumor size \<4 cm PTC, cN1b excluded                                                                                   1--2 cm: 326, 2--4 cm: 55; ETE: 42.5%, multiple: 11.0%, N1a: 36.5%                                                         9.8 yr (5.1--12.2 yr)   Oncologic outcome according to TT vs. lobectomy with propensity score matching of TT group   Contralateral lobe: 3, central node: 3, lateral node: 4
  Vaisman et al. (2011) \[[@b21-ceo-2019-01634]\]      Memorial Sloan-Kettering Cancer Center, USA             NC                                                                                                                      72                                                                  Not performed; CND: 1, LND: 1 included                                       \<4 cm, cN0, normal contralateral lobe in USG                                                                                1 Poorly differentiated ca, 2 follicular ca, 3 Hurthle cell ca included                                                    6.8 yr                  Oncologic outcome between TT vs. lobectomy                                                   Contralateral lobe: 11, contralateral lobe+lateral node: 7, lateral node: 3, operation bed: 2, distant meta: 1
  Tumor size: 1.65 (0.1--4.1); N1a: 8.3%, N1b: 1.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Vaisman et al. (2013) \[[@b22-ceo-2019-01634]\]      Universidale Federal do Rio de Janeiro, Brazil          NC                                                                                                                      70                                                                  No prophylactic ND (44 CND--/19 CND+)                                        DTC \>1 cm with lobectomy                                                                                                    Tumor size: 2.0 (0.2--6.0); 14 follicular ca included, multiple: 15.7%, N1a: 7.1%                                          12 mo (3--28 mo)        Oncologic outcome with lobectomy in DTC                                                      Contralateral lobe: 3
  Xue et al. (2017) \[[@b23-ceo-2019-01634]\]          The First Hospital of Jilin University, China           2005--2006                                                                                                              57                                                                  Routine CND                                                                  Unilateral multifocal PTMC                                                                                                   Tumor size: \>5 mm: 29.82%, ≤5 mm: 70.18%.                                                                                 126±5 mo                Oncologic outcome of multifocal PTMC according to TT vs. lobectomy                           Contralateral lobe: 4, central node: 1
  Foci number: \>3: 15.79%, ≤3, 84.21%, pN1a: 59.65%   Contralateral lobe: 14, entral node: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

CND, central neck dissection; DTC, differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; ETE, extrathyroidal extension; TT, Total thyroidectomy; PTMC, papillary thyroid microcarcinoma; RT, radiation therapy; NC, Not clarified; LND, lateral neck dissection; TSH, thyroid stimulating hormone; USG, ultrasonography.
